Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen

NCT06362720 is registered in ClinicalTrials.gov with Siriraj Hospital as lead sponsor.

NCT NCT06362720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06362720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
Lead sponsor
Siriraj Hospital
Phase
Observational
Overall status
Unknown status
Start date
May 1, 2024
Completion date
December 31, 2024
Enrollment
158 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cmv infection or reactivation after allogenic hsct